(via TheNewswire)

Thrive Precision Health, Inc.
  

Thrive pivots to focus on applying technology to diabetes care.

 

Spokane, WA USA –TheNewswire -October 5, 2023Thrive Global Biosafety Inc. (with subsidiary Thrive Testing and Biosafety Inc., "CNER" or "Company") (OTC:CNER)announced today it has completed a name change of the Company to Thrive Precision Health, Inc.  Thrive Precision Health has two wholly subsidiary companies.  The first subsidiary is Thrive Testing and Biosafety Inc., and the second is called Thrive Precision Health, Inc., incorporated under the State of Hawaii, will be renamed Thrive Precision Health (USA), Inc.

 

While the focus has shifted to diabetes care, the core technology Thrive has licensed and is developing will change how care is delivered to diabetic patients.

  

About Thrive Precision Health Inc.

Thrive Precision Health, Inc. (“Thrive”) is building a global diabetes care powerhouse. We are acquiring established healthcare clinics that already specialize in diabetes care and bringing in three cutting-edge technologies to make them even better. Our goal is to provide top-notch care to patients worldwide with a seamless digital experience. Imagine if your healthcare was as unique as you are. We use AI and quantum biosensors to analyze data down to the molecular level, tailoring treatments and recommendations specifically for you. This means no more one-size-fits-all solutions. Your health decisions will be based on your personal data, ensuring you receive the most effective and personalized care possible.  Leveraging this groundbreaking technology and clinical services will include Wound Care, Neuropathy Care, PIR diabetes care through advanced infusion methods, and conventional and complementary treatment to improve patient outcomes.  All services will be performed within a biosafety-secured facility using our biodefense technology to protect our suspectable patients and staff from bacterial and viral infections.

  

Important Notice Regarding Forward-Looking Statements

 

This press release contains statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements, other than statements of present or historical fact included in this press release, regarding the Company's future financial performance, as well as the Company's strategy, future operations, revenue guidance, projected costs, prospects, plans, and objectives of management are forward-looking statements. When used in this press release, the words "could," "should," "will," "may," "believe," "anticipate," "intend," "estimate," "expect," "project," the negative of such terms and other similar expressions are intended to identify forward-looking statements. However, not all forward-looking statements contain such identifying words. These forward-looking statements are based on management's current expectations and assumptions about future events. They are based on currently available information about the outcome and timing of future events. Except as otherwise required by applicable law, the Company disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release. Nothing in this release is intended to be an offer of sale or purchase of any securities nor a solicitation of any offer for the sale or purchase of any securities.

 

Thrive Precision Health, Inc. (formerly China New Energy Group Company)

 

For more information:  www.thriveprecision.health

 

Contact:

info@thrivebiosafety.com

   

Copyright (c) 2023 TheNewswire - All rights reserved.

Copyright (c) 2023 TheNewswire - All rights reserved., source Press Releases